Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. Common Stock (INVA) is an innovative biopharmaceutical company focused on bringing compelling new medicines to patients in areas of unmet need. Leveraging its significant expertise in development, commercialization, and financial management, Innoviva has established a diverse portfolio that includes royalty assets and strategic healthcare investments.
Innoviva's primary assets are anchored in respiratory therapies, specifically those partnered with Glaxo Group Limited (GSK). The company is entitled to receive royalty revenues from key products such as Relvar®/Breo® Ellipta®, Anoro® Ellipta®, and potentially VI monotherapy if approved and commercialized. These products were jointly developed with GSK, showcasing a strong collaboration that significantly contributes to Innoviva's revenue stream.
In addition to its respiratory portfolio, Innoviva holds a 15% economic interest in future payments made by GSK for early-stage programs partnered with Theravance Biopharma, Inc. This strategic investment underlines Innoviva's commitment to fostering innovation in the biopharmaceutical industry.
More recently, Innoviva has expanded its footprint in critical care and infectious diseases through strategic acquisitions and partnerships. Notably, the company, via its subsidiary Innoviva Strategic Opportunities LLC, has entered into a secured credit agreement with Armata Pharmaceuticals, Inc., providing $35 million to advance Armata's lead therapeutic phage candidates. This financing underscores Innoviva's dedication to supporting groundbreaking therapies for antibiotic-resistant infections.
Furthermore, Innoviva’s product offerings extend beyond respiratory treatments to include other critical healthcare assets, such as Trelegy Ellipta®. The company's well-rounded portfolio ensures a balanced approach to addressing various healthcare challenges.
Innoviva continually strives to maximize shareholder value through strategic investments and partnerships, robust financial performance, and a commitment to advancing innovative medical solutions. For more detailed information about Innoviva, please visit their official website at www.inva.com.
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva (NASDAQ: INVA), has secured exclusive U.S. distribution and licensing rights for Zevtera® (ceftobiprole) from Basilea Pharmaceutica. The FDA-approved advanced-generation cephalosporin antibiotic is notably the only MRSA cephalosporin antibiotic approved for treating adult patients with Staphylococcus aureus bloodstream infections and endocarditis.
The agreement involves a $4 million upfront payment plus tiered royalties and sales milestones. IST plans to launch Zevtera commercially in mid-2025. The drug received FDA approval in April 2024 for three indications: SAB including right-sided infective endocarditis, ABSSSI in adults, and CABP in both adults and pediatric patients.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a leading critical care and infectious disease platform, announced its participation in the Citi 2024 Global Healthcare Conference. CEO Pavel Raifeld will join a fireside chat on December 5, 2024, at 8:45 a.m. Eastern Time in Miami, FL. A live webcast of the chat will be available under the 'Events & Presentations' section on Innoviva's website. The webcast will remain accessible for replay for 90 days.
Innoviva (NASDAQ: INVA), a diversified holding company with a core royalties portfolio and a critical care and infectious disease platform, announced its management's participation in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA.
The event will take place on Wednesday, November 13, 2024, at 10:15 a.m. Pacific Time. A live webcast can be accessed under the 'Events & Presentations' section of Innoviva's Investor Relations website. The webcast will be available for replay for 90 days after the event.
Innoviva reported third quarter 2024 financial results, highlighting strong performance and significant progress. Key points include:
Royalty revenue: $60.5 million from GSK, a 6% year-over-year increase.
Net product sales: $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% growth. GIAPREZA® contributed $13.1 million, XERAVA® $2.3 million, and XACDURO® $4.3 million.
License revenue: $4.6 million from development cost-sharing reimbursements.
Net income: $1.2 million, or $0.02 per share, down from $82.0 million, or $1.26 per share in Q3 2023.
Cash and assets: $260.6 million in cash and equivalents, with $91.1 million in receivables.
Notable achievements include the nomination of XACDURO® for the 2024 Prix Galien USA Award and plans to submit an NDA for zoliflodacin in early 2025.
Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 10:30 a.m. Eastern Time. Additionally, Innoviva will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, at 3:40 p.m. Eastern Time.
Both presentations will be accessible via live webcasts in the Investor Relations section of Innoviva's website. Archived replays will also be available after the events. This participation demonstrates Innoviva's commitment to engaging with investors and showcasing its portfolio, which includes a core royalties segment and a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST).
Innoviva (NASDAQ: INVA) reported strong Q2 2024 financial results, showcasing growth across multiple fronts. Key highlights include:
- GSK royalties of $67.2 million, up from $65.7 million in Q2 2023
- Net product sales of $21.7 million, a 38% year-over-year increase
- License revenue of $14.5 million, including an $8 million milestone payment for XACDURO® approval in China
- Net loss of $34.7 million, primarily due to unfavorable changes in investment fair values
- Completed $100 million share repurchase program
The company's core products, XACDURO® and XERAVA®, received recognition in important treatment guidelines. Innoviva remains focused on enhancing shareholder value through capital allocation and operational excellence.
Innoviva (Nasdaq: INVA), a diversified holding company with a core royalties portfolio and a strong presence in critical care and infectious disease through Innoviva Specialty Therapeutics (IST), announced that its CEO, Pavel Raifeld, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL on June 10, 2024, at 1:20 p.m. Eastern Time. The session will be available via live webcast on the company's Investor Relations webpage and can be replayed for 90 days.
Innoviva, Inc. (NASDAQ: INVA) reported strong first quarter financial results with $61.9 million in GSK royalties, $19.1 million in net product revenues, and a successful pipeline. The company highlighted positive Phase 3 zoliflodacin clinical trial results and key appointments.
Innoviva, Inc. (NASDAQ: INVA) will participate in the BofA Securities Health Care Conference. The company, a holding firm with a core royalties portfolio and a strong presence in critical care and infectious disease treatment, will have its CEO, Pavel Raifeld, present at the conference on May 15, 2024. Interested parties can access a live webcast of the event on the company's Investor Relations website.
FAQ
What is the current stock price of Innoviva (INVA)?
What is the market cap of Innoviva (INVA)?
What does Innoviva, Inc. specialize in?
What are Innoviva's primary products?
Who are Innoviva's main partners?
What recent financial agreements has Innoviva entered into?
How does Innoviva generate revenue?
What is Innoviva's role in the development of respiratory therapies?
What strategic areas is Innoviva investing in?
What is Innoviva’s relationship with Theravance Biopharma?
Where can I find more information about Innoviva?
What are Innoviva's latest projects?
